Indications of Capmatinib (Capatinib)

Capmatinib (Capmatinib) is a targeted drug used to treat certain types of lung cancer. Its main function is to treat advanced or metastatic non-small cell lung cancer (NSCLC) carrying METgene 14 exon skipping mutation (METex14). METGene mutations lead to overexpression or activation of the MET protein, which promotes tumor growth and metastasis in some cancer types.

Main functions and mechanisms

1.Inhibition of MET receptor tyrosine kinase activity: Capatinib (Capatinib) blocks the MET signaling pathway by selectively inhibiting the activity of MET receptor tyrosine kinase. This signaling pathway plays a key role in normal cell function and tumor cell growth. By inhibiting the MET receptor, capatinib (capatinib) can reduce tumor cell proliferation, survival, and migration.

2.Reducing tumor growth and metastasis: Since MET gene mutations can cause abnormal growth and spread of cells, Capatinib (Capatinib) works by inhibiting the abnormal signals caused by this mutation, reducing the growth and metastasis of tumor cells, thereby controlling the progression of cancer.

3.Advantages of targeted therapy: Unlike traditional chemotherapy,Capatinib (Capatinib) is a targeted drug targeting specific gene mutations and has higher selectivity and efficiency. It is designed to target theMETex14 mutation, which makes the treatment more precise, with relatively fewer side effects and better tolerated by patients.

In clinical trials, capmatinib (capatinib) showed significant efficacy. For advanced or metastatic patients carrying METex14 mutationsIn patients with NSCLC capmatinib significantly prolonged progression-free survival and overall survival. Trial results show that capmatinib (capatinib) has a higher objective response rate, that is, a larger proportion of patients have tumors that shrink significantly or disappear completely. This efficacy makescapatinib an important treatment option for these specific patients.